Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke

Neuroendovascular therapy is a common treatment for patients with acute ischemic stroke of the anterior circulation who fail to respond to recombinant tissue plasminogen activator. However, although most hospitals can provide recombinant tissue plasminogen activator therapy, many cannot perform neuroendovascular therapy. Thus, use of a drip-and-ship treatment-liaison system allowing recombinant tissue plasminogen activator-treated patients to be transferred to facilities offering neuroendovascular therapy is important.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research